Botulinum toxin type A for the treatment of head and neck chronic myofascial pain syndrome

Khalifeh, Mohamad; Mehta, Kalpesh; Varguise, Nibu; Suarez-Durall, Piedad; Enciso, Reyes

doi:10.1016/j.adaj.2016.08.022

Cited by 32 publications

(16 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These positive effects appeared to diminish at 7 months. However, in contrast with the systematic review [16], which included neck muscles, the present results showed no significant difference in masticatory muscle pressure algometry values between groups. This indicates that other methods of evaluation should be encouraged (e.g.…”

Section: Discussioncontrasting

confidence: 99%

“…When analyzing duration of treatment, a systematic review and metaanalysis that included only placebo (normal saline solution)-controlled studies [16] reported that botulinum toxin injections reduced pain at 2 to 6 months, but not at 4 to 6 weeks. The primary outcome was pain, as evaluated by VAS; pressure algometry was the secondary outcome.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Incobotulinum toxin type A for treatment of chronic myofascial pain

et al. 2021

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Incobotulinum toxin type A for treatment of chronic myofascial pain

et al. 2021

View full text Add to dashboard Cite

“…The pain rating score was significantly decreased from 5.1 to 2.6 at 12 weeks after the Nabota ® injection. A previous systemic review [ 8 ] documented that pain was reduced by Botulinum toxin A at 2 to 6 months after injection but not at 4 to 6 weeks. Our results showed that, in 75% of patients, the pain score had significantly improved at 12 weeks, and 41.7% of the patients had decreased pain scores at 6 weeks.…”

Section: Discussionmentioning

confidence: 99%

Safety and Efficacy of PrabotulinumtoxinA (Nabota®) Injection for Cervical and Shoulder Girdle Myofascial Pain Syndrome: A Pilot Study

Kim

2018

Toxins

View full text Add to dashboard Cite

Myofascial pain syndrome is a common painful condition encountered in the general population. Previous studies evaluating the efficacy of botulinum toxin for the treatment of myofascial pain syndrome are limited, with variable results. This prospective study investigated the efficacy and safety of direct injection of Prabotulinumtoxin A (Nabota®) into painful muscle groups for cervical and shoulder girdle myofascial pain. Twelve patients with chronic myofascial pain syndrome of the neck and shoulder underwent an injection of Prabotulinumtoxin A. Painful muscles containing trigger points were injected in the mid-belly. Pain scores and quality of life measurements were assessed at baseline, as well as 6 weeks and 12 weeks post-injection. Safety and tolerability were also assessed. This trial is registered under clinical research information service (CRIS) number KCT0001634. Patients injected with Prabotulinumtoxin A showed a significant improvement in pain at 12 weeks (p < 0.001). At 6 weeks, the pain had not significantly improved compared with baseline (p = 0.063). However, at that time, 41.7% of patients were characterized as Prabotulinumtoxin A responders, with a 30% reduction in pain rating score compared to baseline. In the Neck Disability Index scores, the patients demonstrated significant improvement at both 6 weeks and 12 weeks. No serious adverse effects occurred during the study. Prabotulinumtoxin A injection into chronically painful muscles associated with cervical and shoulder girdle myofascial pain syndrome resulted in an improvement in pain scores and quality of life lasting at least 12 weeks. Additionally, the injections were well tolerated. As these are preliminary findings in a pilot study, future studies should carefully consider using randomized, controlled, prospective trials.

show abstract

“…An examination of patients with PIFP for myofascial trigger points that reproduces the patient’s pain is clearly needed. Furthermore, treatment by inactivation of such myofascial trigger points found in PIFP patients by currently known effective techniques that include treatment of neck and shoulder pain, including cervicogenic myofascial pain [ 95 , 96 , 97 , 98 , 99 , 100 , 101 ] should be studied in order to see if PIFP is diminished or eliminated by inactivation of TrPs. A study such as this would allow a determination to be made about the relevance of myofascial trigger points in PIFP.…”

Section: Discussionmentioning

confidence: 99%

Chronic Facial Pain: Trigeminal Neuralgia, Persistent Idiopathic Facial Pain, and Myofascial Pain Syndrome—An Evidence-Based Narrative Review and Etiological Hypothesis

Gerwin

2020

IJERPH

View full text Add to dashboard Cite

Trigeminal neuralgia (TN), the most common form of severe facial pain, may be confused with an ill-defined persistent idiopathic facial pain (PIFP). Facial pain is reviewed and a detailed discussion of TN and PIFP is presented. A possible cause for PIFP is proposed. (1) Methods: Databases were searched for articles related to facial pain, TN, and PIFP. Relevant articles were selected, and all systematic reviews and meta-analyses were included. (2) Discussion: The lifetime prevalence for TN is approximately 0.3% and for PIFP approximately 0.03%. TN is 15–20 times more common in persons with multiple sclerosis. Most cases of TN are caused by neurovascular compression, but a significant number are secondary to inflammation, tumor or trauma. The cause of PIFP remains unknown. Well-established TN treatment protocols include pharmacotherapy, neurotoxin denervation, peripheral nerve ablation, focused radiation, and microvascular decompression, with high rates of relief and varying degrees of adverse outcomes. No such protocols exist for PIFP. (3) Conclusion: PIFP may be confused with TN, but treatment possibilities differ greatly. Head and neck muscle myofascial pain syndrome is suggested as a possible cause of PIFP, a consideration that could open new approaches to treatment.

show abstract

Botulinum toxin type A for the treatment of head and neck chronic myofascial pain syndrome

Cited by 32 publications

References 34 publications

Incobotulinum toxin type A for treatment of chronic myofascial pain

Incobotulinum toxin type A for treatment of chronic myofascial pain

Safety and Efficacy of PrabotulinumtoxinA (Nabota®) Injection for Cervical and Shoulder Girdle Myofascial Pain Syndrome: A Pilot Study

Chronic Facial Pain: Trigeminal Neuralgia, Persistent Idiopathic Facial Pain, and Myofascial Pain Syndrome—An Evidence-Based Narrative Review and Etiological Hypothesis

Contact Info

Product

Resources

About